| PRECLINICAL | evidence | Starvation ketosis following self-administered tirzepatide obtained via online services in a young woman later diagnosed with anorexia nervosa: a case report. | Tirzepatide | — | 2026-06-04 |
| PRECLINICAL | evidence | Micro Doses, Macro Potential? Considerations for Microdosing Tirzepatide in Multi-Dose Pens. | Tirzepatide | — | 2026-06-04 |
| PRECLINICAL | evidence | Disproportionality Analysis of Tirzepatide-Associated Ketoacidosis. | Tirzepatide | — | 2026-06-04 |
| PRECLINICAL | evidence | Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis. | LY3298176 | — | 2026-06-03 |
| PRECLINICAL | evidence | Glucagon-like peptide 1 receptor agonist use and risk of arthroplasty for knee osteoarthritis: retrospective database analysis. | Tirzepatide | — | 2026-06-02 |
| PRECLINICAL | evidence | On the Noninferiority of Tirzepatide: Insights From SURPASS-CVOT. | Tirzepatide | — | 2026-06-02 |
| PRECLINICAL | evidence | The GLP-1 Ceiling and GIP Dividend: Unraveling the Cardio-Metabolic Paradox in SURPASS-CVOT. | Tirzepatide | — | 2026-06-02 |
| PRECLINICAL | evidence | Fat, muscle, and anti-obesity medications in cardiovascular disease prevention. | Tirzepatide | Weight & fat loss | 2026-06-02 |
| PRECLINICAL | evidence | Tirzepatide data: safety first is safety always! | Tirzepatide | — | 2026-06-02 |
| PRECLINICAL | evidence | GLPs Significantly Decrease the Risk of Postoperative Surgical Complications: A TriNetX Retrospective Cohort Study. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Correction: Clinical Implications of Mounjaro (Tirzepatide) for Breast Cancer Detection and Management: A Narrative Review. | Mounjaro | — | 2026-06-01 |
| PRECLINICAL | evidence | The Role of Glucagon-Like Peptide-1 Receptor Agonists in Hair Loss: Clinical Evidence and Proposed Mechanisms. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Clinical Implications of Mounjaro (Tirzepatide) for Breast Cancer Detection and Management: A Narrative Review. | Mounjaro | — | 2026-06-01 |
| PRECLINICAL | evidence | Longitudinal 18F-Fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET) Findings in Korsakoff Syndrome After Rapid Weight Loss During Tirzepatide Therapy: A Case Report. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Joint TOS/OMA/OAC expert guidance statement on the pharmacological management of United States adults with overweight or obesity using the GRADE approach. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Early Tirzepatide Use After Acute Myocardial Infarction or Ischemic Stroke in Patients Without Diabetes: A Real-World Propensity-Matched Study. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Forword for efficacy and safety of tirzepatide in patients with heart failure with preserved ejection fraction: A systematic review and meta-analysis. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Efficacy and safety of Tirzepatide in patients with heart failure with preserved ejection fraction: A systematic review and meta-analysis. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Do GLP-1 Receptor Agonists Sabotage Fat Grafts? : A Scoping Review of GLP-1 Receptor Agonist Effects on Adipocyte Biology and Implications for Autologous Fat Transfer. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | GLP-1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta-Analysis of RCTs. | Tirzepatide | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | Interpreting Post-Discontinuation Trajectories After Semaglutide or Tirzepatide. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. | Tirzepatide | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | Type 2 Diabetes in Pregnancy: Management and Novel Therapies. | Tirzepatide | Glycemic control | 2026-06-01 |
| PRECLINICAL | evidence | Eating Disorders in the GLP-1 Era: A Spotlight on Emerging Clinical Risks, Research Gaps, and Practice Priorities. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Tirzepatide as adjunct therapy in patients with type 1 diabetes: a systematic review and meta-analysis. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Clinical Management of Weight Regain and Cardiometabolic Consequences After Discontinuation of GLP-1 Receptor Agonists. | Tirzepatide | Glycemic control | 2026-06-01 |
| PRECLINICAL | evidence | Response To "Superior Cerebrovascular Outcomes with Tirzepatide Versus Semaglutide: A Call for Cautious Interpretation of Observational Data". | Tirzepatide | Glycemic control | 2026-06-01 |
| PRECLINICAL | evidence | Real-World Cardiovascular Outcomes of Obesity Treatment With Tirzepatide Versus Semaglutide in Non-Diabetic Adults. | Tirzepatide | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | Real-World Weight-Loss Outcomes in Weight-Reduced Patients Treated With Tirzepatide. | Tirzepatide | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | Efficacy of tirzepatide, lanifibranor, and resmetirom in metabolic dysfunction-associated steatotic liver disease: a meta-analysis of high-quality randomized controlled trials. | Tirzepatide | Liver health | 2026-06-01 |
| PRECLINICAL | evidence | Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide: A critical appraisal. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Dose-response analysis of tirzepatide and acute pancreatitis: An international systematic review and quantitative meta-analysis of randomised trials. | Tirzepatide | Glycemic control | 2026-06-01 |
| PRECLINICAL | evidence | Ethical Issues Related to the Use of GLP-1 Receptor Agonists Such as Ozempic and Mounjaro: Impact on Individuals and Society at Large. | Mounjaro | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | Childhood obesity and cardiac risk in youth: Emerging challenges toward 2050. | Tirzepatide | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | Health-Related Quality of Life and Work-Related Outcomes in People with Obesity or Overweight Treated with Tirzepatide or Other Obesity Medications: United States Results from the Adelphi Real World Obesity Disease Specific Programme. | Tirzepatide | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | GLP-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Bridging Hepatic and Cardiovascular Outcomes. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Anti-Obesity Pharmacotherapy and Emerging Multimodal Interventions for Obstructive Sleep Apnea. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Complete Skin Remission of Lichen Planus With Tirzepatide. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Psychosocial Outcomes in Telemedicine and Long-Acting Incretin-Specific Behavioral Intervention. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | GLP-1-based therapies and limb outcomes in PAD: a systematic review and meta-analysis of real-world studies. | Tirzepatide | Glycemic control | 2026-06-01 |
| PRECLINICAL | evidence | Integrated Evidence from VigiBase and Clinical Trials: A Comprehensive Pharmacovigilance Analysis of Seven Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs). | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Glucagon-Like Peptide-1 Receptor Agonists Across the Heart Failure Spectrum: A Systematic Review and Meta-Analysis. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Tirzepatide and Reduced Risk of Diabetic Retinopathy and Related Complications: A Multicenter US Cohort Study. | Tirzepatide | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | Persistence-Dependent Effectiveness of Tirzepatide on the Cardio-Metabolic-Kidney Syndrome Outcomes in Obesity: Real-World Evidence from the United Arab Emirates. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Body image in the age of GLP-1s: Emerging questions for research and practice. | Tirzepatide | Weight & fat loss | 2026-06-01 |
| PRECLINICAL | evidence | Possible Attenuation of Early Weight Loss During Tirzepatide Therapy in a Patient Treated With Levosulpiride: A Case Report and Mechanistic Hypothesis. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Understanding Weight Regain After Tirzepatide Withdrawal. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | A Systematic Review Identifying Critical Evidence Gaps in Reporting Dietary Change in Randomized Controlled Trials Prescribing Liraglutide, Semaglutide, or Tirzepatide. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Pityriasis Lichenoides et Varioliformis Acuta Associated With Tirzepatide: A First Report. | Tirzepatide | — | 2026-06-01 |
| PRECLINICAL | evidence | Data-driven prioritization of high-risk individuals for weight loss interventions. | Tirzepatide | Weight & fat loss | 2026-06-01 |